Journal Article

Efficacy of Clarithromycin and Ethambutol for Mycobacterium avium Complex Pulmonary Disease. A Preliminary Study

Miwa, Seiichi, Toyoshima, Mikio, Yasuda, Kazumasa, Yokomura, Koshi, Inui, Naoki, Chida, Kingo, Hayakawa, Hiroshi, Suda, Takafumi, Yamada, Takashi, Shirai, Toshihiro, Shirai, Masahiro, Masuda, Masafumi

2014

Overview

Patients with Mycobacterium avium complex pulmonary disease are frequently administered a combination of clarithromycin, ethambutol, and rifampicin. However, rifampicin is known to reduce the serum levels of clarithromycin. It remains unclear whether a reduction in clarithromycin serum levels influences the clinical outcome of the Mycobacterium avium complex pulmonary disease treatment regimen. To compare a three-drug regimen (clarithromycin, ethambutol, and rifampicin) to a two-drug regimen (clarithromycin and ethambutol) for the treatment of Mycobacterium avium lung disease. In a preliminary open-label study, we randomly assigned newly diagnosed, but as-yet untreated, patients with disease caused by Mycobacterium avium complex without HIV infection to either the three-drug or the two-drug regimen for 12 months. The primary endpoint was the conversion of sputum cultures to negative after 12 months of treatment. Patient data were analyzed using the intention-to-treat method. Of 119 eligible patients, 59 were assigned to the three-drug regimen and 60 to the two-drug regimen. The rate of sputum culture conversion was 40.6% with the three-drug regimen and 55.0% with the two-drug regimen (difference, -14.4% [95% confidence interval, -32.1 to 3.4]). The incidence of adverse events leading to the discontinuation of treatment was 37.2 and 26.6% for the three-drug and the two-drug regimens, respectively. This preliminary study suggests that treatment with clarithromycin and ethambutol is not inferior to treatment with clarithromycin, ethambutol, and rifampicin for Mycobacterium avium complex lung disease. Our findings justify a larger clinical trial to compare long-term clinical outcomes for the two treatment regimens. Clinical trial registered with http://www.umin.ac.jp/english/ (UMIN000002819).

• Publisher: Oxford University Press
• Subject: Aged / Aged, 80 and over / Anti-Bacterial Agents - therapeutic use / Antibiotics, Antitubercular - therapeutic use / Antitubercular Agents - therapeutic use / Clarithromycin - therapeutic use / Drug Therapy, Combination / Ethambutol - therapeutic use / Female / Human immunodeficiency virus / Humans / Male / Middle Aged / Mycobacterium avium / Mycobacterium avium Complex - isolation & purification / Mycobacterium avium-intracellulare Infection - drug therapy / Rifampin - therapeutic use / Sputum - microbiology / Treatment Outcome / Tuberculosis, Pulmonary - drug therapy